WO2016048107A1 - Composition pharmaceutique pour la prévention ou le traitement de maladies immunitaires ou de maladies inflammatoires, comprenant des cellules souches traitées par de l'interféron gamma ou de l'interleukine-1 beta, ou une culture de celles-ci - Google Patents

Composition pharmaceutique pour la prévention ou le traitement de maladies immunitaires ou de maladies inflammatoires, comprenant des cellules souches traitées par de l'interféron gamma ou de l'interleukine-1 beta, ou une culture de celles-ci Download PDF

Info

Publication number
WO2016048107A1
WO2016048107A1 PCT/KR2015/010253 KR2015010253W WO2016048107A1 WO 2016048107 A1 WO2016048107 A1 WO 2016048107A1 KR 2015010253 W KR2015010253 W KR 2015010253W WO 2016048107 A1 WO2016048107 A1 WO 2016048107A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
cells
ifn
interleukin
interferon
Prior art date
Application number
PCT/KR2015/010253
Other languages
English (en)
Korean (ko)
Inventor
김유리
이승희
서광원
강경선
Original Assignee
주식회사 강스템바이오텍
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 강스템바이오텍 filed Critical 주식회사 강스템바이오텍
Publication of WO2016048107A1 publication Critical patent/WO2016048107A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells

Definitions

  • the present invention is directed to the prevention of immune diseases and inflammatory diseases, including stem cells cultured by adding cytokines of interferon-gamma (IFN- ⁇ ) and / or interleukin-1 beta (IL-1 ⁇ ) to stem cells or their cultures. Or to a pharmaceutical composition for treatment.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • the immune system is building a defense system composed of various cells to protect the human body from internal and external pathogens, which is achieved through the specific function of each cell and signal transmission between each cell.
  • the body's immune system can be broadly divided into immune tolerance, which suppresses and regulates immunity, and immune response, which promotes immunity.
  • the two immune functions are balanced to achieve immunological homeostasis. You lose. However, for some reason, their balance is broken, resulting in immune and inflammatory diseases if the immune response is more advanced than immune tolerance.
  • Immunosuppression for the prevention or treatment of autoimmune diseases or inflammatory diseases include specific inhibitors and nonspecific inhibitors that inhibit only the response, and theoretically, the action of the specific inhibitor should be excellent, but nonspecific inhibitors are mainly used.
  • the most commonly used immunosuppressive agents are cyclosporine (Neoral, Cipol A), azacioprine (imuran) and prednisolone (a type of steroid). The three were found to have fewer side effects and the highest immunosuppressive effects when used together when used separately.
  • various immunosuppressive agents such as FK 506, RATG, OKT3, and Cellcept have been developed and used.
  • immunosuppressive agents inhibit immunosuppression by inhibiting several processes such as phagocytosis of antigen by macrophages, antigen recognition by lymphocytes, cell division, T cell and B cell division, and antibody production. Cause. Most of them have antitumor activity because they inhibit cell division through the mediation of DNA disorders and the inhibition of DNA synthesis.
  • the typical side effects are hypertension and nephrotoxicity (decrease in kidney function), and the high incidence of these side effects has caused problems such as observing the course when used sufficiently.
  • Other side effects rarely include tremor, seizures, hepatitis, biliary retention, increased blood uric acid, decreased muscle strength, hypertrichosis, and gingival hypertrophy.
  • azachioprine inhibits bone marrow function, such as decreased white blood cell count, anemia, and platelet reduction.
  • pancreatitis, hepatitis, and biliary retention may rarely cause hair loss and fever.
  • Prednisolone one of the steroid agents, was the first to be used among immunosuppressants and has the broadest inhibitory action. It may increase appetite, increase muscles in the shoulders and back, and temporarily bring happiness, but these steroids not only promote atherosclerosis, but also cause high blood pressure, gastric ulcers, diabetes, growth inhibition, osteoporosis, cataracts, and glaucoma. The drug to watch out for.
  • biopharmaceuticals As a therapeutic agent to overcome the side effects, biopharmaceuticals have been in the spotlight, and the representative ones are stem cell therapeutics.
  • Mesenchymal stem cell research has been reported for the application of stem cell differentiation ability to treat damaged joint tissues for the treatment of regeneration and anti-inflammatory (US Pat. No. 6835377), but the mechanism of treatment is clearly identified. The cure is a rare reality.
  • endotoxins such as lipopolysaccharide (LPS) is a substance that induces the production of proinflammatory factors in the cell, and promotes the production of inflammatory cytokines (inflammatory cytokines) causing an inflammatory response. That is, when an external stimulus capable of causing an inflammatory response is applied, expression of inflammatory cytokines such as TNF- ⁇ is induced, and the generated inflammatory cytokines stimulate expression of genes encoding iNOS and COX-2, Induces an inflammatory response by producing NO and PGE 2 substances involved in the inflammatory response.
  • pretreatment of these inflammatory cytokines to stem cells has yet to be described for the mechanisms that prevent or treat inflammatory or immune diseases by increasing the expression of inflammatory regulators or cell migration-related factors secreted from stem cells. Not known until.
  • the inventors of the present invention when cultured (pretreatment) by adding a cytokine such as interferon-gamma or interleukin-1 beta to stem cells, the expression of inflammatory regulators or cell migration-related factors secreted from stem cells significantly increased, and thus The present invention has been completed by confirming that stem cells can be used as a cell therapy for the prevention or treatment of immune diseases or inflammatory diseases.
  • a cytokine such as interferon-gamma or interleukin-1 beta
  • One object of the present invention is 10 to 20 ng / ml interferon-gamma (IFN- ⁇ ) and 2.5 to 10 ng / ml in stem cells, which is economical and free of side effects that can replace conventional immunosuppressive and inflammatory inhibitors.
  • IL-1 ⁇ interleukin-1 beta
  • Another object of the present invention is a method for preparing stem cells or cultures thereof, the method comprising culturing by adding inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ). It is to provide a method for producing a stem cell or a culture thereof characterized in that the cultivation of from 20 to 20 ng / ml of IFN- ⁇ and 2.5 to 10 ng / ml of IL-1 ⁇ for 12 to 36 hours.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • Another object of the present invention is 1 ⁇ 10 6 to 1 ⁇ 10 9 stem cells cultured with the addition of inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ); And a composition for single administration of stem cells containing 1 to 100 ml of a culture medium in which stem cells are cultured by treating inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ).
  • the culture medium to provide a stem cell treatment effect of two to three times compared to a single dose of stem cells, to provide a composition for administration of stem cells first.
  • Still another object of the present invention is to provide a composition for single administration of stem cells containing the stem cells 1 ⁇ 10 6 to 1 ⁇ 10 9 .
  • Still another object of the present invention is a composition for inhibiting proliferation of mononuclear cells, including the stem cells or cultures thereof; Or it provides a method for inhibiting the proliferation ability of monocytes comprising the step of treating the stem cells or cultures thereof to the tissue to be transplanted.
  • Another object of the present invention is a composition for increasing the expression or activity of IDO (Indoleamine 2,3-dioxygenase), including the stem cells or cultures thereof; Or treating stem cells or cultures thereof added with inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1beta (IL-1 ⁇ ) to increase the expression or activity of IDO. It is.
  • IDO Indoleamine 2,3-dioxygenase
  • Still another object of the present invention is a composition for inhibiting differentiation of CD4 + T cells into Th1 cells or Th17 cells, including the stem cells or cultures thereof; Or Th4 of CD4 + T cells comprising treating CD4 + T cells with stem cells or cultures thereof added with inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ). It is to provide a method for inhibiting differentiation into 1 cell or Th17 cell.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • Another object of the present invention is a composition for increasing the migration or recruitment of CD4 + T cells comprising the stem cells or cultures thereof; Or migrating CD4 + T cells, comprising treating CD4 + T cells with stem cells or cultures thereof added with inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ). It provides a way to increase migration or recruitment.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • Still another object of the present invention is a method of targeting stem cells to secondary lymphoid organs (SLO), wherein the stem cells contain inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ). Culturing by addition; And administering the stem cells, wherein the stem cells targeted to the secondary lymphoid organs are CCR7 compared to stem cells not treated with interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ).
  • CC-chemokine receptor type 7 A method characterized by increased gene expression.
  • Another object of the present invention is an inflammatory cytokine of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ), which is administered immediately after the onset of the acute graft-versus-host disease or within 5 days of onset.
  • Pharmaceutical composition for treating acute graft-versus-host disease containing stem cells or cultures thereof added thereto; Or stem cells or cultures thereof cultured with inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ) immediately after onset or within 5 days of onset of acute graft-versus-host disease. It provides a method for treating acute graft-versus-host disease, comprising the step of administering.
  • Still another object of the present invention is to prevent or treat Crohn's disease, which contains stem cells cultured with inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ) or cultures thereof. It is to provide a pharmaceutical composition.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • Still another object of the present invention is to provide an IDO-mediated immune disease, comprising stem cells or cultures thereof added with inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1beta (IL-1 ⁇ ). It is to provide a pharmaceutical composition for preventing or treating inflammatory diseases.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1beta
  • Still another object of the present invention is to provide a method for preparing an immunosuppressant or anti-inflammatory agent, comprising culturing by adding interferon-gamma (IFN- ⁇ ) and interleukin-1beta (IL-1 ⁇ ) to stem cells.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1beta
  • Another object of the present invention is to incubate stem cells in medium containing inflammatory cytokines COX-2 (Cyclooxygenase-2), IDO (Indoleamine 2,3-dioxygenase), PGE 2 (Prostaglandin E2) and CCR7 It provides a method for mass production of one or more proteins selected from the group consisting of (CC-chemokine receptor type 7).
  • COX-2 Cyclooxygenase-2
  • IDO Indoleamine 2,3-dioxygenase
  • PGE 2 Prostaglandin E2
  • CCR7 It provides a method for mass production of one or more proteins selected from the group consisting of (CC-chemokine receptor type 7).
  • Stem cells or cultures thereof according to the present invention can be used for the prevention or treatment of immune diseases and inflammatory diseases.
  • stem cells according to the present invention can be produced in a simple, economical and improved yield without chemical processing factors or factors related to cell migration.
  • Stem cells or cultures thereof according to the present invention is a cell therapy which can be used economically without side effects and replaces existing immunosuppressive agents and inflammatory inhibitors with known side effects such as autoimmune diseases such as Clones disease, rheumatoid arthritis, atopy, etc. It can be used for the prevention or treatment of diseases and inflammatory diseases.
  • Figure 1a is a diagram showing the expression level of the immunoregulatory factor COX-2 mRNA when complex treatment of cord blood-derived mesenchymal stem cells IFN- ⁇ , IL-1 ⁇ , TNF- ⁇ or IL-2, respectively.
  • Figure 1b is a diagram showing the expression level of the immunoregulatory factor PGE 2 when the combination of umbilical cord blood-derived mesenchymal stem cells IFN- ⁇ , IL-1 ⁇ , TNF- ⁇ or IL-2, respectively.
  • Figure 1c is a diagram showing the immunomodulator IDO activity level when the combination of cord blood-derived mesenchymal stem cells IFN- ⁇ , IL-1 ⁇ , TNF- ⁇ or IL-2, respectively.
  • 1D is a diagram showing the proliferation level of human mononuclear cells when mixed lymphocyte reaction was performed after complex treatment of umbilical cord blood-derived mesenchymal stem cells with IFN- ⁇ , IL-1 ⁇ , TNF- ⁇ or IL-2, respectively.
  • Figure 2a is a diagram showing the expression level of mRNA of IDO over each time after treatment with 20ng / ml of IFN- ⁇ and 10ng / ml of IL-1 ⁇ for 3, 6, 12, 24 hours simultaneously.
  • Figure 2b is a diagram showing the expression level of PGE 2 according to each time after treatment with IFN- ⁇ 20ng / ml and IL-1 ⁇ 10ng / ml for 3, 6, 12, 24 hours at the same time.
  • Figure 3a is a diagram showing the expression level of mRNA of COX-2 according to each concentration after treatment with IFN- ⁇ 5, 10, 20ng / ml and IL-1 ⁇ 2.5, 5, 10ng / ml for 24 hours at the same time to be.
  • Figure 3b is a diagram showing the expression level of mRNA of IDO according to each concentration after treatment with 5 times, IFN- ⁇ 5, 10, 20ng / ml and IL-1 ⁇ 2.5, 5, 10ng / ml to the stem cells for 24 hours at the same time.
  • Figure 4 is a diagram showing the results of measuring the expression level of the immunoregulatory factors PGE 2 and NOD2 of mesenchymal stem cells isolated from different tissues (bone marrow, fat, umbilical cord blood) of human.
  • Figure 5a is a diagram showing the expression level of PGE 2 after inhibiting each factor using 1-Methyltryptophan (1-MT) as an IDO inhibitor and Indomethacin as a PGE 2 inhibitor.
  • Figure 5b is a diagram showing the expression level of IDO after inhibiting each factor using 1-Methyltryptophan (1-MT) as an IDO inhibitor and Indomethacin as a PGE 2 inhibitor.
  • Figure 5c is a diagram showing the level of monocyte proliferation after inhibition of each factor using 1-Methyltryptophan (1-MT) as the IDO inhibitor and Indomethacin as the PGE 2 inhibitor.
  • Figure 5d is a diagram showing the expression level of IL-17 after inhibiting each factor using 1-Methyltryptophan (1-MT) as the IDO inhibitor and Indomethacin as the PGE 2 inhibitor.
  • Figure 6 shows the differentiation of IFN- ⁇ and Th17 cells secreted during the differentiation process to Th1 cells in the experiment to confirm the effect of differentiation of Th4 cells or Th17 cells of CD4 + T cells co-cultured with mesenchymal stem cells
  • Figure 6 shows the secretion amount of interleukin-17 (IL-17) secreted in the process.
  • IL-17 interleukin-17
  • Figure 7 is a diagram showing the results of co-culture by fluorescent staining of mesenchymal stem cells and CD4 + T cells cultured by pretreatment with IFN- ⁇ or / and IL-1 ⁇ .
  • FIG. 8 is a diagram showing the mobility of CD4 + T cells with respect to the culture medium secreted from the cells through the culture for 3 days after replacing the mesenchymal stem cells pre-treated with IFN- ⁇ or / and IL-1 ⁇ with fresh medium.
  • FIG. 9 is a diagram showing the expression level of CCR7 with each time after treatment with IFN- ⁇ and / or IL-1 ⁇ for 6, 12, 24 hours.
  • FIG. 10 is a diagram illustrating a manufacturing process of an animal model of acute graft-versus-host disease, that is, a process of inducing acute graft-versus-host disease and administering stem cells pretreated with IFN- ⁇ and / or IL-1 ⁇ .
  • FIG. 11 is a diagram showing the change in survival rate following administration of mesenchymal stem cells pretreated with IFN- ⁇ and / or IL-1 ⁇ in an acute graft-versus-host disease animal model.
  • FIG. 12 is a diagram showing the change in GVHD score according to the administration of mesenchymal stem cells pretreated with IFN- ⁇ and / or IL-1 ⁇ in acute graft-versus-host disease animal model.
  • 13A-13D show IFN- ⁇ and / or IL-1 ⁇ in skin tissue (a), liver tissue (b), small intestine tissue (c) and their total tissue (d), respectively, of the acute graft-versus-host disease animal model.
  • the therapeutic effect of pretreatment with mesenchymal stem cells is shown through histopathological evaluation.
  • FIG. 14 is a diagram showing changes in survival rate according to administration of mesenchymal stem cells pretreated with IFN- ⁇ and / or IL-1 ⁇ in Crohn's disease animal model.
  • FIG. 15 is a diagram showing the effect of weight loss upon administration of mesenchymal stem cells pretreated with IFN- ⁇ and / or IL-1 ⁇ to Crohn's disease animal model.
  • the present invention is a stem cell cultured by treating the inflammatory cytokine in the stem cell or its culture; Or it provides a pharmaceutical composition for the prevention or treatment of immune diseases or inflammatory diseases comprising the same.
  • inflammatory cytokines specifically interferon-gamma (IFN- ⁇ ), interleukin-1 beta (IL-1 ⁇ ), or both of these factors are treated to stem cells
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • CCR7 inflammatory cell inhibitors secreted from the stem cells Expression of (COX-2, PGE 2 , IDO) and factors related to cell migration (migration) (CCR7) was increased, thereby regulating immunity and inflammation.
  • COX-2, PGE 2 , IDO factors related to cell migration (migration)
  • CCR7 cell migration
  • the present invention confirms that the stem cells treated with inflammatory cytokines and their cultures can be used as cell therapy for immunoregulation and inflammation control, stem cells cultured by adding inflammatory cytokines to stem cells or It can be used as a pharmaceutical composition for the prevention or treatment of immune diseases or inflammatory diseases comprising the culture.
  • proinflammatory cytokine is a generic name for cytokines that cause inflammatory reactions occurring in the body, typically tumor necrosis factor-alpha (TNF- ⁇ ), interferons (IFNs), Interleukins (ILs), monocyte chemoattractant protein, and the like.
  • TNF- ⁇ tumor necrosis factor-alpha
  • IFNs interferons
  • ILs Interleukins
  • monocyte chemoattractant protein and the like.
  • the inflammatory cytokine may be IFN- ⁇ and / or IL-1 ⁇ , but is not limited thereto.
  • "adding and culturing" an inflammatory cytokine may be, for example, by culturing by adding the inflammatory cytokine to a medium of stem cells.
  • the cytokine is specifically 0.1 to 100 ng / ml , 1 to 50 ng / ml, 2 to 25 ng / ml, 2.5 to 20 ng / ml, or 5 to 10 ng / ml.
  • IFN- ⁇ may be treated at 10 to 20 ng / ml, and IL-1 ⁇ at 2.5 to 10 ng / ml.
  • the concentration of the treated cytokine When the concentration of the treated cytokine is lower than the concentration, the secretion of immunomodulators secreted from stem cells such as IDO and PGE 2 may not be sufficient, resulting in a slight or no increase in immunomodulatory capacity. On the other hand, when the concentration of the treated cytokine is higher than the concentration, there is a disadvantage that it may affect the characteristics of the cells, thereby promoting aging of stem cells, suppression of proliferation, reduction of differentiation capacity, and the like.
  • the treatment (culture) time of these cytokines can be incubated for 0.5 to 96 hours, 2 to 72 hours, 3 to 48 hours, 6 to 36 hours, 12 to 36 hours, or 12 to 24 hours. If the cytokine treatment time is shorter than the above, the secretion of immunomodulators secreted from stem cells such as IDO and PGE 2 may not be sufficient, resulting in a slight or no increase in immunomodulatory capacity. On the other hand, if the treatment time of the cytokine is longer than the above, there is a disadvantage in that it may affect the characteristics of the cells, thereby promoting aging of stem cells, suppressing proliferation, and decreasing the differentiation ability.
  • the stem cells of the present invention may be cultured 10 to 20 ng / ml of IFN- ⁇ and 2.5 to 10 ng / ml of IL-1 ⁇ for 12 to 36 hours.
  • stem cells may be cells having the ability to differentiate into various tissues, that is, 'undifferentiated cells'.
  • the stem cells are human adult stem cells, human pluripotent stem cells, human pluripotent stem cells, induced pluripotent stem cells (induced pluripotent stem cells), animal embryonic stem cells or animal adult stem cells Can be.
  • Multipotent stem cells are multipotent stem cells derived from various adult cells such as bone marrow, umbilical cord blood, placenta (or placental tissue cells), fat (or adipose tissue cells), and the like.
  • various studies have been conducted for the development of mesenchymal stem cells derived from bone marrow as cell therapeutics due to the differentiation that can be differentiated into adipose tissue, bone / cartilage tissue, and muscle tissue.
  • adult stem cells may be mesenchymal stem cells, mesenchymal stromal cells derived from human tissues, mesenchymal stem cells derived from human tissues, multipotent stem cells, or amniotic epithelial cells, and mesenchymal stem cells may be umbilical cord cells.
  • Umbilical cord blood, bone marrow, fat, muscle, nerves, skin, amniotic membrane and placenta can be derived from mesenchymal stem cells (mesenchymal stem cells), in particular, may be derived from human, especially human umbilical cord blood It may be derived from Human Umbilical Cord Blood Mesenchymal Stem Cell (hUCB-MSC).
  • the expression level of immune and inflammatory regulators (COX-2, PGE 2 ) is significantly higher in cord blood-derived mesenchymal stem cells derived from humans than in other tissues (FIG. 4).
  • the method of obtaining stem cells from each of the derivatives may be by a method known in the art, and is not limited to the method of the embodiment of the present invention.
  • culture may include both cell culture medium containing stem cells, culture supernatants from which stem cells are removed from the cell culture solution, and dilutions thereof.
  • the composition of the culture may further include not only components necessary for conventional stem cell culture, but also components that synergistically act on stem cell proliferation, and thus the composition may be easily carried out by those skilled in the art. Can be selected.
  • IFN- ⁇ and IL-1 ⁇ may be added and cultured at the same time, or after the addition of IFN- ⁇ , IL-1 ⁇ may be added, or after IL-1 ⁇ addition. It is also possible to culture by adding - ⁇ , and the order of addition is not limited.
  • a medium used for culturing the stem cells a conventional medium known in the art to be suitable for culturing stem cells may be used.
  • DMEM Denbecco's modified Eagle medium
  • Keratinocyte-SFM Keratinocyte serum free medium
  • the stem cell medium may be supplemented with an additive.
  • an additive may contain neutral buffers (such as phosphates and / or high concentrations of bicarbonate) and protein nutrients (such as serum, such as FBS, serum substitutes, albumin, or essential and non-essential amino acids, such as glutamine) in isotonic solutions.
  • neutral buffers such as phosphates and / or high concentrations of bicarbonate
  • protein nutrients such as serum, such as FBS, serum substitutes, albumin, or essential and non-essential amino acids, such as glutamine
  • lipids fatty acids, cholesterol, HDL or LDL extracts of serum
  • other components found in most preservative media of this kind such as insulin or transferrin, nucleosides or nucleotides, pyruvate salts, any ionized form or salt
  • Sugar sources such as glucose, selenium, glucocorticoids such as hydrocortisone and / or reducing agents such as ⁇ -mercaptoethanol.
  • adult stem cells treated with IFN- ⁇ and / or IL-1 ⁇ significantly increase the expression of COX-2, IDO, PGE 2 and CCR7, which are known as inflammatory regulators or cell migration factors.
  • IFN- ⁇ and / or IL-1 ⁇ treatment in the present invention was confirmed that the main effect of the mixed lymphocyte inhibitory effect by increasing the expression of IDO (Fig. 5c).
  • the stem cells of the present invention or the culture thereof has a mononuclear cell proliferation inhibitory effect according to the mononuclear cell proliferation inhibitory composition comprising the same, or the step of treating the stem cells or the culture of the present invention to the tissue to be transplanted It is possible to provide a method of inhibiting the proliferative ability of a mononuclear cell containing (Example 6).
  • stem cells of the present invention or the culture thereof have an activity of inhibiting the differentiation of CD4 + T cells into Th 1 cells or Th17 cells
  • interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ) Stem cells cultured with the addition of inflammatory cytokines or their cultures are in the form of a composition for inhibiting differentiation of CD4 + T cells into Th 1 cells or Th17 cells, or the stem cells or their cultures as CD4 + T cells It can be provided in the form of a method for inhibiting the differentiation of CD4 + T cells into Th 1 cells or Th 17 cells comprising the step of (Example 7).
  • stem cells of the present invention or cultures thereof have an activity of increasing migration or recruitment of CD4 + T cells
  • interferon-gamma (IFN- ⁇ ) and interleukin-1beta (IL-1 ⁇ ) are in the form of a composition for increasing migration or recruitment of CD4 + T cells, or treating the stem cells or cultures thereof with CD4 + T cells. It may be provided in the form of a method for increasing the migration (migration) or recruitment (recruitment) of CD4 + T cells comprising a,
  • the present invention is a method for targeting stem cells to secondary lymphoid organs (SLO), the stem cells by adding inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ) Culturing; And administering the stem cells, wherein the stem cells targeted to the secondary lymphoid organs are CCR7 compared to stem cells not treated with interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ).
  • CC-chemokine receptor type 7 A method characterized by increased gene expression can be provided (Example 8).
  • Stem cells that are targeted may include artificially genetically engineered.
  • stem cells cultured by the addition of the inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ) of the present invention or cultures thereof, for increasing the expression or activity of IDO It may be provided in the form of a composition or in the form of a method of increasing the expression or activity of IDO by treating the stem cells or cultures thereof (Example 5).
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • the stem cells and the cultures thereof according to the present invention are useful for the prevention and treatment of immune diseases or inflammatory diseases, particularly IDO-mediated immune diseases or inflammatory diseases.
  • IDO-mediated disease refers to an immune disease or an inflammatory disease that may occur due to the inability to normally express an IDO gene or to secrete a protein thereof in an immune or inflammation-related mechanism.
  • inflammatory disease is a generic term for inflammation as the main lesion, but is not limited thereto, specifically, swelling, dermatitis, allergy, atopic, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, Gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, spondylitis spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, hay salt, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome or multiple sclerosis.
  • immune disease is a disease that is a problem when a specific immune response occurs, but is not limited thereto, and specifically, may be autoimmune disease, transplant rejection, and graft-versus-host disease.
  • the immune disease or inflammatory disease may be autoimmune disease, transplant rejection, graft-versus-host disease, arthritis, bacterial infection, sepsis or inflammation, and the autoimmune disease is Crohn's disease, erythema disease, atopic dermatitis, rheumatoid arthritis, Hashimoto's thyroiditis , Pernicious anemia, Edison's disease, type 1 diabetes, lupus, chronic fatigue syndrome, fibromyalgia, hypothyroidism and hypertension, scleroderma, Behcet's disease, inflammatory bowel disease, multiple sclerosis, myasthenia gravis, Meniere's syndrome , Guilian-Barre syndrome, Sjogren's syndrome, vitiligo, endometriosis, psoriasis, vitiligo, epithelial scleroderma, asthma or ulcerative colitis.
  • prevention is any action that inhibits or delays the onset of an immune disease or inflammatory disease by administration of the composition
  • treatment is any improvement or benefit of the symptoms of an immune disease or inflammatory disease by administration of the composition. It is an act.
  • the stem cells or cultures thereof according to the present invention is 1.0 ⁇ 10 5 to 1.0 ⁇ 10 9 , specifically 1.0 ⁇ 10 6 to 1.0 ⁇ 10 8 , more specifically 1.0 ⁇ 10 7 per ml. Cells may be included.
  • Stem cells or cultures thereof according to the invention can be used unfrozen or frozen for future use. If frozen, standard cryopreservatives (eg DMSO, glycerol, Epilife cell freezing medium (Cascade Biologics)) can be added to the cell population before freezing.
  • standard cryopreservatives eg DMSO, glycerol, Epilife cell freezing medium (Cascade Biologics)
  • the stem cells or cultures thereof according to the present invention may be administered in a unit dosage form suitable for administration in the body of a patient according to a conventional method in the pharmaceutical field, the formulation may be administered once or several times. Dosages include effective dosages. Suitable formulations for this purpose are parenteral formulations such as injections such as ampoules for injection, injections such as infusion bags, and sprays such as aerosol formulations.
  • the injection ampoule may be mixed with the injection solution immediately before use, and physiological saline, glucose, mannitol, and Ringer's solution may be used as the injection solution.
  • the infusion bag may also be made of polyvinyl chloride or polyethylene and may be Baxter, Becton Dickinson, Medcep, National Hospital Products or Terumo.
  • the injection bag of the yarn can be illustrated.
  • one or more pharmaceutically acceptable inert carriers such as preservatives, analgesic agents, solubilizers or stabilizers in the case of injections, etc. It may further include a base, excipients, lubricants or preservatives.
  • the stem cells, cultures or pharmaceutical preparations thereof according to the present invention are prepared with or in combination with other stem cells used for transplantation and other uses using administration methods commonly used in the art. It may be administered in the form, specifically, it is possible to engraft or implant directly to the disease site of the patient in need of treatment, or to implant or inject directly into the abdominal cavity, but is not limited thereto.
  • the administration can be both non-surgical administration using a catheter and surgical administration such as injection or transplantation after dissection of the disease site, but non-surgical administration using a catheter is more appropriate.
  • parenteral administration for example, in addition to direct lesions, transplantation by intravascular injection, which is a general method of hematopoietic stem cell transplantation, is also possible according to a conventional method.
  • the single dose of the stem cells is 1.0 ⁇ 10 4 to 1.0 ⁇ 10 10 cells / kg body weight, specifically 1.0 ⁇ 10 5 to 1.0 ⁇ 10 9 cells / kg body weight, more specifically 1.0 ⁇ 10 6 to 1.0 ⁇ 10 8 cells / kg body weight may be administered once or in several doses.
  • the actual dosage of the active ingredient should be determined in light of several relevant factors such as the disease to be treated, the severity of the disease, the route of administration, the patient's weight, age and gender, and therefore the dosage may It does not limit the scope of the present invention in terms of aspects.
  • one containing 1.0 ⁇ 10 6 to 1.0 ⁇ 10 9 stem cells cultured with the addition of inflammatory cytokines of interferon-gamma (IFN- ⁇ ) and interleukin-1 beta (IL-1 ⁇ ) of the present invention It may be provided in a dosage.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • the stem cell culture when included in the means of administration, such as a cell therapy agent, the number or amount of stem cells required to have an equivalent effect is remarkably at the level of 1/2 to 1/10, 1/2 to 1/3. Reduced, which may have a much more economical effect on formulation (Example 9).
  • the stem cells or cultures thereof may be treated immediately after the onset of the disease to be treated, such as an immune disease or an inflammatory disease, in particular, an inflammatory bowel disease such as acute graft-versus-host disease or Crohn's disease. It can be administered within 5 days, 3 days, 2 days or 1 day.
  • an immune disease or an inflammatory disease such as acute graft-versus-host disease or Crohn's disease.
  • an inflammatory bowel disease such as acute graft-versus-host disease or Crohn's disease.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1beta
  • Examples 9-1 and 10-1 As a result of administration of stem cells or cultures thereof, it was confirmed that the symptoms of these lesions showed improved therapeutic activity (Examples 9-1 and 10-1). This is expected to be related to the significantly increased expression of inflammatory regulators 12 to 24 hours after treatment with interferon-gamma (IFN- ⁇ ) and interleukin-1beta (IL-1 ⁇ ).
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1beta
  • the inflammatory cytokine-treated stem cells according to the present invention can be inhibited by administering a stem cell and its culture, and the inflammation can be controlled.
  • the present invention provides a culture by adding inflammatory cytokines to stem cells.
  • Provided are a method for inhibiting an immune response or an inflammatory response of a subject or a method for preventing or treating an immune disease or an inflammatory disease, comprising administering one stem cell or a culture thereof to the subject.
  • subject or “individual” includes, but is not limited to, mammals including cattle, dogs, pigs, chickens, sheep, horses, and humans.
  • administration of stem cells or cultures thereof added with inflammatory cytokines may be intraperitoneal or vascular administration, direct administration to a lesion, or administration in a synovial cavity.
  • Inhibition of the immune response or inflammatory response may be characterized in that the prevention or treatment of immune diseases or inflammatory diseases.
  • the present invention provides a method for preparing an immunosuppressant or anti-inflammatory agent, comprising culturing by adding inflammatory cytokines to stem cells.
  • the immunosuppressant or anti-inflammatory agent may be in the form of a cell therapy.
  • an "immunosuppressant” is an agent capable of treating an immune disease by inhibiting an immune response with an agent comprising a stem cell or a culture obtained by adding an inflammatory cytokine to the stem cell and culturing the stem cell. You can be the best.
  • an anti-inflammatory agent may be an agent capable of treating inflammatory diseases by inhibiting inflammation with a stem cell obtained by culturing by adding inflammatory cytokines to stem cells or an agent comprising the culture thereof. have.
  • the present invention includes the step of culturing stem cells in medium containing inflammatory cytokines, COX-2 (Cyclooxygenase-) characterized in that the expression of inflammatory regulators in the stem cells is increased during the culture 2), a mass production method of one or more proteins selected from the group consisting of IDO (Indoleamine 2,3-dioxygenase), PGE 2 (Prostaglandin E2) and CCR7 (CC-chemokine receptor type 7).
  • IDO Indoleamine 2,3-dioxygenase
  • PGE 2 Prostaglandin E2
  • CCR7 CC-chemokine receptor type 7
  • the recovery of the protein can be obtained by collecting the culture medium of the stem cells, centrifugation and filtration to remove the cells and suspended solids, and recovering the remaining supernatant.
  • the present invention provides an implant comprising a stem cell and an inflammatory cytokine.
  • a "graft” is a substance that can be transplanted into a human body or an animal, which isolates the damaged site from the outside or contains transplanted cells or secreted therapeutic material.
  • Such implants may be provided with various materials used in the art such as synthetic polymers and natural materials having biodegradability as a support for tissue engineering. Since the implant of the present invention contains stem cells and inflammatory cytokines, there is an advantage of not causing an immune rejection reaction or an inflammatory response due to the implant. Therefore, even without the administration of a separate immune rejection inhibitor or anti-inflammatory agent to suppress the immune rejection or inflammatory response that may occur when various implants are implanted in the body, the transplanted implant is stable without the immune rejection reaction or inflammation in vivo It can engulf as.
  • the present invention provides a transplant in which the stem cells are removed after culturing stem cells by adding inflammatory cytokines on a support.
  • the present invention provides a method for producing an implant comprising culturing by adding inflammatory cytokines to stem cells on a support.
  • the method may further include removing stem cells after the culturing step.
  • the present invention is a stem cell; And a cytokine of 10-20 ng / ml interferon-gamma (IFN- ⁇ ) and 2.5-10 ng / ml interleukin-1 beta (IL-1 ⁇ ).
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • the complex can be used as a cell therapy.
  • the present invention is added to the stem cells by adding a cytokine of 10 to 20 ng / ml of interferon-gamma (IFN- ⁇ ) and 2.5 to 10 ng / ml of interleukin-1 beta (IL-1 ⁇ ) It provides a cultured stem cell or a culture thereof.
  • a cytokine 10 to 20 ng / ml of interferon-gamma (IFN- ⁇ ) and 2.5 to 10 ng / ml of interleukin-1 beta (IL-1 ⁇ ) It provides a cultured stem cell or a culture thereof.
  • IFN- ⁇ interferon-gamma
  • IL-1 ⁇ interleukin-1 beta
  • the culture may exert an effect capable of preventing or treating an immune disease or an inflammatory disease, and an inflammation regulator or cell migration-related factors such as COX-2, IDO, PGE 2 and CCR7 may be present.
  • the present invention provides a 10 to 20 ng / ml interferon-gamma (IFN- ⁇ ) and 2.5 to 10 ng in stem cells for the preparation of a pharmaceutical composition for the prevention or treatment of immune or inflammatory diseases
  • IFN- ⁇ interferon-gamma
  • stem cells or cultures thereof cultured with the addition of / ml cytokine of interleukin-1 beta (IL-1 ⁇ ).
  • IL-1 ⁇ interleukin-1 beta
  • Umbilical cord blood was mixed with Hetasep TM solution at a ratio of 5: 1 and left at room temperature for 40 minutes. Then, the supernatant was carefully placed on Ficoll and centrifuged at 2500 rpm for 20 minutes. After centrifugation, the monocyte layer was collected, washed twice with PBS, and coated with fibronectin at a concentration of 2 ⁇ 10 5 to 2 ⁇ 10 6 cells / cm 2 using EGM-2 medium containing 20% fetal bovine serum. Seeded on. After 3 days, the non-adherent cells were removed and colony formation was observed by replacing the medium every 2-3 days. The colonies thus formed were passaged to obtain mesenchymal stem cells. As a result of observing expression markers using FACS on the obtained mesenchymal stem cells, the mesenchymal stem cells were characterized by expressing ZNF281 (zinc finger protein 281) in addition to the markers of normal mesenchymal stem cells.
  • ZNF281 zinc finger protein 281
  • IDO converts L-tryptophan to N-formylkynurenine, which is produced by hydrolysis by reaction with 30% (wt / vol) trichloroacetic acid.
  • mixed lymphocyte reaction was performed to confirm the proliferation level of human mononuclear cells (hMNC) obtained through primary culture.
  • the mixed lymphocyte reaction is described in Example 5 below.
  • COX-2 a representative immunomodulator
  • IL-1 ⁇ compared to other cytokines
  • PGE 2 an immunomodulator regulated by COX- 2
  • IDO another immunomodulator
  • immune regulators COX-2 and IDO By maximizing the expression of immune regulators COX-2 and IDO from stem cells through pretreatment of stem cells with IFN- ⁇ and IL-1 ⁇ , they can be used as cell therapeutics with enhanced immunosuppressive and anti-inflammatory effects. It suggests that there is.
  • Example 2 IFN - ⁇ and IL- 1 ⁇ According to processing time Immunomodulatory factors Expression level analysis
  • IFN- ⁇ 20ng / ml and IL-1 ⁇ 10ng / ml were treated simultaneously with stem cells for 3, 6, 12, and 24 hours, and then the expression levels of mRNA of IDO were compared using real-time RT-PCR.
  • comparative analysis was performed using ELISA to determine the expression level of PGE 2 .
  • the expression level of IDO showed the highest expression level 24 hours after treatment (FIG. 2A).
  • the expression level of PGE 2 was confirmed to show the highest expression level 12 hours after treatment (Fig. 2b). This resulted in the highest amount of PGE 2 secreted in IFN- ⁇ and IL-1 ⁇ pretreated stem cells at 12 hours, and when treated for more than 12 hours, the secretion could be lowered. The longer the hour, the more the secretion increases in time within 24 hours.
  • Example 3 IFN - ⁇ and IL- 1 ⁇ Treatment concentration Immunomodulatory factors Expression level analysis
  • IFN- Simultaneous treatment of ⁇ 5, 10, 20ng / ml and IL-1 ⁇ 2.5, 5, 10ng / ml with stem cells for 24 hours was followed by real-time RT-PCR expression of mRNA levels of COX-2 and IDO mRNA. Comparative analysis.
  • mesenchymal stem cells were isolated from different tissues (bone marrow, fat, umbilical cord blood) of human.
  • Cord blood-derived mesenchymal stem cells were obtained by the method described in Preparation Example, and bone marrow-derived mesenchymal stem cells were distributed from Yonsei University College of Medicine Severance Hospital Cell Therapy Center and used.
  • fat-derived mesenchymal stem cells are described in Ji-Won Jung et al , Cell Mol Life Sci. 2010 Apr; 67 (7): 1165-1176. Obtained by a method known in the art.
  • Example 5 IFN - ⁇ and IL- 1 ⁇ Stem Cells by Concurrent Treatment Immunosuppressive ability Enhancement analysis
  • hMSC Mesenchymal stem cells obtained in the above preparations were seeded in 6-well plates at a concentration of 3 ⁇ 10 5 cells / well, and after 24 hours, 2 ⁇ M of 5-aza was treated for 24 hours.
  • the mesenchymal stem cells were treated with 25 mg / ml mitomycin C, and the cells were plated in 96-well plates at a concentration of 1 ⁇ 10 4 cells / well.
  • Monocytes (MNC) were activated using Concanavalin A (ConA) and seeded onto plates at a concentration of 5 ⁇ 10 4 cells / well.
  • transwells 24-well plates, Corning, Corning, NY
  • pores of 0.4 ⁇ m size were used.
  • Monocytes (MNC) were activated using ConA and plated at a concentration of 1 ⁇ 10 6 cells / well in the lower chamber.
  • Mesenchymal stem cells treated with 5-aza were seeded at a concentration of 1 ⁇ 10 5 cells / well in the upper chamber.
  • the proliferation rate of monocytes was analyzed using BrdU assay (Bromodeoxyuridine kit, Roche, Upper Bavaria, Germany).
  • IFN- ⁇ -treated mesenchymal stem cells showed an effect of further inhibiting the mixed lymphocyte response regardless of the simultaneous treatment of IL-1 ⁇ (Fig. 5c).
  • the inhibitory effect was reduced to the control level when treated with IDO inhibitor 1-MT, while the inhibitory effect was partially reduced when treated with Indomethacin, an inhibitor of PGE 2 (FIG. 5C).
  • Example 6 IFN - ⁇ and IL- 1 ⁇ Stem Cells by Concurrent Treatment Th1 Of Th17 Immunosuppressive assay
  • the lower chamber of the co-culture plate which is a 24-well plate
  • 1 ⁇ 10 6 sorted CD4 + T cells were placed in the upper chamber, and the mesenchymal stem cells of each culture condition were placed in the upper chamber.
  • the lower chamber is equipped with a composition of a suitable medium so that CD4 + T cells are differentiated into Th1 cells or Th17 cells, and then cultured for 4 days for Th1 cells and 7 days for Th17 cells, and then recovered the culture medium to measure the secreted factors. The differentiation of T cells was confirmed.
  • the composition of each culture medium is shown in Table 2 below.
  • IFN- ⁇ and / or IL-1 ⁇ -treated mesenchymal stem cells and CD4 + T cells were pre-treated with mesenchymal stem cells and CD4 + T cells pretreated with IFN- ⁇ and / or IL-1 ⁇ .
  • IFN- ⁇ and / or IL-1 ⁇ -treated mesenchymal stem cells and CD4 + T cells were pre-treated with mesenchymal stem cells and CD4 + T cells pretreated with IFN- ⁇ and / or IL-1 ⁇ .
  • the secretion amount of IFN- ⁇ and IL-17 was further reduced, so that the effect of inhibiting the differentiation of CD4 + T cells into Th1 cells and Th17 cells was better (FIG. 6).
  • Example 7 Change in T Cell Mobility by Stem Cells Treated with IFN- ⁇ and IL-1 ⁇
  • mesenchymal stem cells and monocytes cultured in culture medium containing the two cytokines were co-cultured for 4 hours by fluorescent staining.
  • the mesenchymal stem cells pre-treated with the IFN- ⁇ and / or IL-1 ⁇ were confirmed to recruit more CD4 + T cells than the mesenchymal stem cells cultured in the non-treated medium. (FIG. 7).
  • CCR7 CC-chemokine receptor 7
  • SLOs secondary lymphoid organs
  • CCR7 can enhance the immune regulatory function by moving the mesenchymal stem cells to secondary lymphoid organs.
  • CCR7 CC-chemokine receptor 7
  • Example 9 acute Graft-versus-host disease (Acute GVHD) In the induced animal model IFN to determine the therapeutic effect of stem cells treated with - ⁇ and IL-1 ⁇
  • mice C57 / BL6 mouse (Donor), BDF1 (Recipient) mice that purchased 8-week-old mice, followed by a 7-day acclimation period, at 9 weeks of age. It was used for the experiment. Bone marrow and spleen were collected at the expense of C57 / BL6 mouse (Donor), and 10 ⁇ 10 6 bone marrow cells and 2 ⁇ 10 6 splenic T cells were transferred to BDF1 (Recipient) [F1 of C57BL / 6 X DBA / 2]. Implantation caused acute graft-versus-host disease.
  • a solvent control or test substance was administered in a single vein into the microvein of the mouse model. Dosing timing and dosage for each group is shown in Figure 10 and Table 4 below.
  • cytokine-treated stem cells when the confluency of the cells in adherent culture reached about 50% -70%, 20ng / ml of IFN- ⁇ and 5ng / ml of IL-1 ⁇ were incubated for 24 hours. The cells were harvested and washed three times before administration.
  • the solvent control agent and the test substance were administered on the third day after inducing acute graft-versus-host disease, and GVHD scores were measured at two check-points per week.
  • GVHD scores were measured at two check-points per week.
  • Repeated measures ANOVA was performed and the statistical significance between the control group and the test group was tested by the Greenhouse-Geisser method (p ⁇ 0.05).
  • Tukey's method was additionally performed for post test.
  • the survival rate did not show a difference between the control group and the test group, and it was confirmed that the addition of the culture medium did not worsen the survival rate when compared between the groups (FIG. 11).
  • the total number of mesenchymal stem cells administered was 3 ⁇ 10 6 or more, and the symptoms of acute GVHD were significantly reduced. It was confirmed that the number of 1 ⁇ 10 6 significantly reduced the symptoms of acute GVHD (Fig. 12).
  • Example 10 in animal models of Crohn's disease IFN - ⁇ and IL- 1 ⁇ Confirmation of treatment effect of treated stem cells
  • DSS dextran sulphate sodium
  • cytokine-treated stem cells when the confluency of the cells in adherent culture reached about 50% -70%, 20ng / ml of IFN- ⁇ and 5ng / ml of IL-1 ⁇ were incubated for 24 hours. The cells were harvested and washed three times before administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement de maladies immunitaires et de maladies inflammatoires, comprenant un type de cellules souches ou une culture de celles-ci, les cellules souches étant cultivées en ajoutant aux cellules souches des cytokines proinflammatoires, l'interféron-gamma et l'interleukine-1 beta.
PCT/KR2015/010253 2014-09-25 2015-09-25 Composition pharmaceutique pour la prévention ou le traitement de maladies immunitaires ou de maladies inflammatoires, comprenant des cellules souches traitées par de l'interféron gamma ou de l'interleukine-1 beta, ou une culture de celles-ci WO2016048107A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140128178 2014-09-25
KR10-2014-0128178 2014-09-25

Publications (1)

Publication Number Publication Date
WO2016048107A1 true WO2016048107A1 (fr) 2016-03-31

Family

ID=55581522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/010253 WO2016048107A1 (fr) 2014-09-25 2015-09-25 Composition pharmaceutique pour la prévention ou le traitement de maladies immunitaires ou de maladies inflammatoires, comprenant des cellules souches traitées par de l'interféron gamma ou de l'interleukine-1 beta, ou une culture de celles-ci

Country Status (2)

Country Link
KR (1) KR20160037113A (fr)
WO (1) WO2016048107A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110088623A (zh) * 2016-10-17 2019-08-02 社会福祉法人三星生命公益财团 选择用于治疗免疫病症的高效干细胞的方法
JP2019531281A (ja) * 2016-09-07 2019-10-31 エスシーエム ライフサイエンス カンパニー リミテッド 炎症刺激された間葉系幹細胞を含む免疫疾患または炎症疾患の予防または治療用薬学的組成物
CN111601881A (zh) * 2018-01-05 2020-08-28 财团法人峨山社会福祉财团 包含利用干扰素γ预处理的诱导多能干细胞来源的间充质干细胞及来源于其的外泌体的用于改善、预防或治疗皮肤疾病的组合物
CN113151164A (zh) * 2021-05-08 2021-07-23 中山大学 一种msc的培养基添加剂及其应用
US20220152121A1 (en) * 2020-11-18 2022-05-19 National Yang Ming Chiao Tung University Composition and Use of Interleukin Stimulated Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Rheumatoid Arthritis
CN115210363A (zh) * 2020-01-06 2022-10-18 Scm生命科学有限公司 用于增强干细胞功能的组合物
CN115518077A (zh) * 2022-09-28 2022-12-27 苏州大学 一种治疗炎症性肠病的细胞药物
CN116139279A (zh) * 2023-01-06 2023-05-23 南京鼓楼医院 C1inh在治疗宫腔粘连中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102082745B1 (ko) * 2018-05-08 2020-02-28 주식회사 휴코드 항염증 성분을 분비하는 줄기세포 배양방법 및 그 줄기세포 배양액을 포함하는 항염증 조성물
KR102260243B1 (ko) * 2020-07-22 2021-06-03 (주)세렌라이프 효능이 증진된 줄기세포를 포함하는 항암용 조성물
CN113832099A (zh) * 2021-10-13 2021-12-24 浙江领蔚生物技术有限公司 用于制备治疗类风湿性关节炎药物的间充质干细胞制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130096661A (ko) * 2012-02-22 2013-08-30 주식회사 강스템홀딩스 줄기세포를 유효 성분으로 함유하는 면역 질환 또는 염증 질환의 예방 또는 치료용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130096661A (ko) * 2012-02-22 2013-08-30 주식회사 강스템홀딩스 줄기세포를 유효 성분으로 함유하는 면역 질환 또는 염증 질환의 예방 또는 치료용 조성물

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRAUN, D. ET AL.: "A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic- cell maturation", BLOOD, vol. 106, no. 7, 2005, pages 2375 - 2381, XP002367564, DOI: doi:10.1182/blood-2005-03-0979 *
HADDAD, R. ET AL.: "Mechanisms of T- cell immunosuppression by mesenchymal stromal cells: what do we know so far?", BIOMED RESEARCH INTERNATIONAL, vol. 2014, no. 216806, June 2014 (2014-06-01), pages 1 - 14 *
LING, W. ET AL.: "Mesenchymal stem cells use IDO to regulate immunity in tumor microenvironment", CANCER RESEARCH, vol. 74, no. 5, March 2014 (2014-03-01), pages 1576 - 1587 *
WAINWRIGHT, D. A. ET AL.: "IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival", CLINICAL CANCER RESEARCH, vol. 18, no. 22, 2012, pages 6110 - 6121 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7212371B2 (ja) 2016-09-07 2023-01-25 エスシーエム ライフサイエンス カンパニー リミテッド 炎症刺激された間葉系幹細胞を含む免疫疾患または炎症疾患の予防または治療用薬学的組成物
JP2019531281A (ja) * 2016-09-07 2019-10-31 エスシーエム ライフサイエンス カンパニー リミテッド 炎症刺激された間葉系幹細胞を含む免疫疾患または炎症疾患の予防または治療用薬学的組成物
CN110088623B (zh) * 2016-10-17 2022-08-09 细胞生命有限公司 选择用于治疗免疫病症的高效干细胞的方法
CN110088623A (zh) * 2016-10-17 2019-08-02 社会福祉法人三星生命公益财团 选择用于治疗免疫病症的高效干细胞的方法
EP3736327A4 (fr) * 2018-01-05 2021-04-07 The Asan Foundation Composition pour améliorer, prévenir ou traiter une maladie de la peau comprenant des cellules souches mésenchymateuses dérivées de cellules souches pluripotentes induites prétraitées par de l'interféron gamma et exosomes dérivés de celle-ci
CN111601881A (zh) * 2018-01-05 2020-08-28 财团法人峨山社会福祉财团 包含利用干扰素γ预处理的诱导多能干细胞来源的间充质干细胞及来源于其的外泌体的用于改善、预防或治疗皮肤疾病的组合物
US11865141B2 (en) 2018-01-05 2024-01-09 The Asan Foundation Composition for improving, preventing or treating skin disease comprising induced pluripotency stem cell-derived mesenchymal stem cells pretreated with interferon gamma and exosomes derived therefrom
CN111601881B (zh) * 2018-01-05 2024-06-21 财团法人峨山社会福祉财团 包含利用干扰素γ预处理的诱导多能干细胞来源的间充质干细胞及来源于其的外泌体的用于改善、预防或治疗皮肤疾病的组合物
CN115210363A (zh) * 2020-01-06 2022-10-18 Scm生命科学有限公司 用于增强干细胞功能的组合物
EP4089164A4 (fr) * 2020-01-06 2024-03-06 SCM Lifescience Co., Ltd. Composition de renforcement de fonction de cellule souche
US20220152121A1 (en) * 2020-11-18 2022-05-19 National Yang Ming Chiao Tung University Composition and Use of Interleukin Stimulated Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Rheumatoid Arthritis
CN113151164A (zh) * 2021-05-08 2021-07-23 中山大学 一种msc的培养基添加剂及其应用
CN113151164B (zh) * 2021-05-08 2023-08-18 中山大学 一种msc的培养基添加剂及其应用
CN115518077A (zh) * 2022-09-28 2022-12-27 苏州大学 一种治疗炎症性肠病的细胞药物
CN116139279A (zh) * 2023-01-06 2023-05-23 南京鼓楼医院 C1inh在治疗宫腔粘连中的应用

Also Published As

Publication number Publication date
KR20160037113A (ko) 2016-04-05

Similar Documents

Publication Publication Date Title
WO2016048107A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies immunitaires ou de maladies inflammatoires, comprenant des cellules souches traitées par de l'interféron gamma ou de l'interleukine-1 beta, ou une culture de celles-ci
WO2012026712A2 (fr) Composition pharmaceutique utilisée dans la prophylaxie ou le traitement de maladies immunitaires ou inflammatoires, contenant des cellules souches traitées par agoniste du nod2 ou un de leurs produits mis en culture
WO2018074758A2 (fr) Procédé pour le tri de cellules souches hautement efficaces pour le traitement de trouble immunitaire
WO2018097540A2 (fr) Kit à ajout de milieu de culture de cellules immunitaires sans sérum, méthode de culture de cellules immunitaires utilisant ledit kit, culture de cellules immunitaires sans sérum obtenue au moyen dudit kit ou de ladite méthode de culture, et composition cosmétique comprenant ladite culture
WO2019117633A1 (fr) Composition cosmétique et composition pharmaceutique pour atténuer la dermatite atopique, la chute des cheveux et les plaies ou réduire les rides de la peau
WO2018048220A1 (fr) Composition pharmaceutique comprenant cellule souche mésenchymateuse stimulée par l'inflammation pour la prévention ou le traitement d'une maladie immunitaire ou d'une maladie inflammatoire
WO2022103138A1 (fr) Composition pour la prévention ou le traitement du cancer comprenant du bifidobacterium longum rapo (kctc13773bp)
WO2020101361A1 (fr) Procédé de culture de cellules tueuses naturelles dérivées de sang de cordon ombilical au moyen de lymphocytes t transformés
WO2019198995A1 (fr) Procédé de conversion à base d'exosomes pour cellules immunitaires
WO2017146538A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par des lymphocytes t régulateurs
WO2022092915A1 (fr) Composition destinée à la prévention et au traitement de maladies immunitaires contenant du gdf15 en tant que principe actif
WO2015167243A1 (fr) Nouveau composé ayant un effet thérapeutique sur les maladies immunitaires et utilisation de ce composé
WO2015023147A1 (fr) Cellule souche mésenchymateuse traitée par un inhibiteur de signal mtor/stat3 ayant une activité immunomodulatrice, et composition pour thérapie cellulaire la comprenant, destinée à prévenir ou traiter des troubles immuns
WO2016117960A1 (fr) Cellules souches mésenchymateuses surexprimées par grim19 efficaces dans le traitement d'une maladie immunitaire, et leur utilisation
WO2015023165A1 (fr) Composite de régulation d'une inflammation et cellules souches mésenchymateuse stabilisées ayant une fonction optimisée de régulation de l'immunité par blocage de la molécule de signalisation stat3
WO2023113541A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer ou d'une maladie inflammatoire
WO2023022569A1 (fr) Méthode de traitement de maladies immunitaires au moyen d'un inhibiteur de la calcineurine et de cellules souches
WO2023120844A1 (fr) Composition pour la prolifération en masse de cellules tueuses naturelles, comprenant un nouveau peptide, et procédé de prolifération de masse de cellules tueuses naturelles à l'aide de celle-ci
WO2016027990A1 (fr) Composition pharmaceutique comprenant dusp5 en tant que substance active pour prévenir ou traiter des maladies métaboliques osseuses
WO2022108390A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de troubles immunitaires dans lesquels l'expression de smile est réduite, contenant du biguanide en tant que principe actif
WO2022131742A1 (fr) Exosomes dérivés de cellules traitées avec un matériau induisant un stress du réticulum endoplasmique et leur utilisation
WO2019027214A9 (fr) Cellule souche mésenchymateuses allogéniques et utilisation associée
WO2018143649A1 (fr) Composition pharmaceutique pour prévenir ou traiter une maladie auto-immune, et son procédé de production
WO2021107635A1 (fr) Composition de traitement anticancéreux, comprenant des cellules nk et une protéine de fusion qui comporte une protéine il-2 et une protéine cd80
WO2016048052A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies immunitaires ou de maladies inflammatoires, comprenant une cellule souche traitée avec des granules de mastocytes ou leur culture

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15843462

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15843462

Country of ref document: EP

Kind code of ref document: A1